Positron emission tomography as a tool for translational research in oncology

Molecular Imaging and Biology

Volumn 6, Issue 4, 2004, Pages 214-224

  Stahl, Alexander ^a,b   Wieder, Hinrich ^a   Piert, Morand ^a   Wester, Hans Jürgen ^a   Senekowitsch Schmidtke, Reingard ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hypoxia; PET CT; Therapy monitoring; Translational research; Tumor proliferation

Indexed keywords

3' FLUOROTHYMIDINE; ACETIC ACID; ANTINEOPLASTIC AGENT; CARBON 11; CD20 ANTIGEN; FLUORODEOXYGLUCOSE F 18; INDIUM 111; IODINE 131; LIPOCORTIN 5; METHIONINE; NITROIMIDAZOLE DERIVATIVE; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; THIOSEMICARBAZONE DERIVATIVE; TRACER; TYROSINE; YTTRIUM 90;

APOPTOSIS; B CELL LYMPHOMA; BRAIN CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CELL PROLIFERATION; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG POTENTIATION; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; HYPOXIA; INDIVIDUALIZATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VASCULARIZATION;

EID: 3543136565     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mibio.2004.04.003     Document Type: Article

References (72)

1. Hany T.F. Steinert H.C. Goerres G.W. et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results Radiology 225 2002 575-581
2. Israel O. Mor M. Gaitini D. et al. Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG J. Nucl Med. 43 2002 1129-1136
3. Lardinois D. Weder W. Hany T.F. et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography N. Engl. J. Med. 348 2003 2500-2507
4. Kaim A.H. Burger C. Ganter C.C. et al. PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report Radiology 221 2001 818-821
5. Grosu A.L. Feldmann H. Dick S. et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas Int. J. Radiat. Oncol. Biol. Phys. 54 2002 842-854
6. Sobottka S.B. Bredow J. Beuthien-Baumann B. et al. Comparison of functional brain PET images and intraoperative brain-mapping data using image-guided surgery Comput. Aided Surg. 7 2002 317-325
7. Sure U. Benes L. Riegel T. Schulte D.M. Bertalanffy H. Image fusion for skull base neuronavigation. Technical note Neurol. Med. Chir. (Tokyo) 42 2002 458-461 discussion 462
8. Grosu A.L. Lachner R. Wiedenmann N. et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and (11)C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience Int. J. Radiat. Oncol. Biol. Phys. 56 2003 1450-1463
9. Ung Y.C. Ehrlich L.E. Ganguli S.N. 18FDG hybrid PET and CT fusion improves target volume definition in treatment planning for carcinomas of the anal canal Int. J. Radiat. Oncol. Biol. Phys. 50 2001-1416
10. Chapman J.D. Bradley J.D. Eary J.F. et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium Int. J. Radiat. Oncol. Biol. Phys. 55 2003 294-301
11. Warburg O. The metabolism of tumors 1930 Constable & Co. London
12. Hofer C. Laubenbacher C. Block T. et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur. Urol. 36 1999 31-35
13. Torizuka T. Tamaki N. Inokuma T. et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET J. Nucl. Med. 36 1995 1811-1817
14. Adams S. Baum R. Rink T. et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur. J. Nucl. Med. 25 1998 79-83
15. Higashi K. Ueda Y. Seki H. et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma J. Nucl. Med. 39 1998 1016-1020
16. Bender H. Schomburg A. Albers P. et al. Possible role of FDG-PET in the evaluation of urologic malignancies Anticancer Res. 17 1997 1655-1660
17. Berger K.L. Nicholson S.A. Dehdashti F. et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features AJR Am. J. Roentgenol. 174 2000 1005-1008
18. Stahl A. Ott K. Weber W.A. et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings Eur. J. Nucl. Med. Mol. Imaging. 30 2003 288-295
19. Wieder H. Ott K. Zimmermann F. et al. PET imaging with [11C]methyl- L-methionine for therapy monitoring in patients with rectal cancer Eur. J. Nucl. Med. Mol. Imaging. 29 2002 789-796
20. Wester H.J. Herz M. Weber W. et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging J. Nucl. Med. 40 1999 205-212
21. Weber W.A. Wester H.J. Grosu A.L. et al. O-(2-[18F] fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study Eur. J. Nucl. Med. 27 2000 542-549
22. Nunez R. Macapinlac H.A. Yeung H.W. et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer J. Nucl. Med. 43 2002 46-55
23. Rau F.C. Weber W.A. Wester H.J. et al. O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes Eur. J. Nucl. Med. Mol. Imaging 29 2002 1039-1046
24. Buyse M. Thirion P. Carlson R.W. et al. Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in cancer Lancet 356 2000 373-378
25. Weber W.A. Petersen V. Schmidt B. et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J. Clin. Oncol. 21 2003 2651-2657
26. Findlay M. Young H. Cunningham D. et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colo-rectal cancer liver metastases: correlation with tumor response to fluorouracil J. Clin. Oncol. 14 1996 700-708
27. Brucher B.L. Weber W. Bauer M. et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography Ann. Surg. 233 2001 300-309
28. Flamen P. Van Cutsem E. Lerut A. et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer Ann. Oncol. 13 2002 361-368
29. Downey R.J. Akhurst T. Ilson D. et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial J. Clin. Oncol. 21 2003 428-432
30. Weber W.A. Ott K. Becker K. et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J. Clin. Oncol. 19 2001 3058-3065
31. Young H. Baum R. Cremerius U. et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur. J. Cancer 35 1999 1773-1782
32. Lindholm P. Leskinen-Kallio S. Grenman R. et al. Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and [11C]methionine Int. J. Radiat. Oncol. Biol. Phys. 32 1995 787-794
33. de Jong I.J. Pruim J. Elsinga P.H. et al. Visualization of prostate cancer with 11C-choline positron emission tomography Eur. Urol. 42 2002 18-23
34. de Jong I.J. Pruim J. Elsinga P.H. et al. Visualization of bladder cancer using (11)C-choline PET: first clinical experience Eur. J. Nucl. Med. Mol. Imaging. 29 2002 1283-1288
35. de Jong I.J. Pruim J. Elsinga P.H. et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET J. Nucl. Med. 44 2003 331-335
36. Oyama N. Miller T.R. Dehdashti F. et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse J. Nucl. Med. 44 2003 549-555
37. Yoshimoto M. Waki A. Yonekura Y. et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells Nucl. Med. Biol. 28 2001 117-122
38. Kotzerke J. Volkmer B.G. Neumaier B. et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer Eur. J. Nucl. Med. Mol. Imaging 29 2002 1380-1384
39. Fricke E. Machtens S. Hofmann M. et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients Eur. J. Nucl. Med. Mol. Imaging 30 2003 607-611
40. Senekowitsch-Schmidtke R. Ruth F. Bernatz S. Radiolabeled thymidine: a sensitive tracer for early tumor response and recurrence after irradiation J. Nucl. Med. 40 1999 1702-1705
41. Senekowitsch-Schmidtke R. Matzen K. Truckenbrodt R. et al. Tumor cell spheroids as a model for evaluation of metabolic changes after irradiation J. Nucl. Med. 39 1998 1762-1768
42. Seitz U. Wagner M. Neumaier B. et al. Evaluation of pyrimidine metabolizing enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines Eur. J. Nucl. Med. Mol. Imaging 29 2002 1174-1181
43. Lu L. Samuelsson L. Bergstrom M. et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers J. Nucl. Med. 43 2002 1688-1698
44. Buck A.K. Halter G. Schirrmeister H. et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG J. Nucl. Med. 44 2003 1426-1431
45. Wagner M. Seitz U. Buck A. et al. 3′-[18F]fluoro3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease Cancer Res. 63 2003 2681-2687
46. Pawlak W. Zolnierek J. Sarosiek T. et al. Antisense therapy in cancer Cancer Treat. Rev. 26 2000 333-350
47. Jansen B. Schlagbauer-Wadl H. Brown B.D. et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice Nat. Med. 4 1998 232-234
48. Jansen B. Wacheck V. Heere-Ress E. et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy Lancet 356 2000 1728-1733
49. Blankenberg F.G. Strauss H.W. Will imaging of apoptosis play a role in clinical care? A tale of mice and men Apoptosis. 6 2001 117-123
50. Glaser M. Collingridge D.R. Aboagye E.O. et al. Iodine-124 labeled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography Appl. Radiat. Isot. 58 2003 55-62
51. Barthel H. Cleij M.C. Collingridge D.R. et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography Cancer Res. 63 2003 3791-3798
52. Belhocine T. Steinmetz N. Hustinx R. et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis Clin. Cancer Res. 8 2002 2766-2774
53. Reiser M. Diehl V. Current treatment of follicular non-Hodgkin's lymphoma Eur. J. Cancer. 38 2002 1167-1172
54. Cremonesi M. Ferrari M. Chinol M. et al. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience Q. J. Nucl. Med. 44 2000 325-332
55. Kaminski M.S. Estes J. Zasadny K.R. et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 96 2000 1259-1266
56. Reubi J.C. Waser B. Schaer J.C. et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur. J. Nucl. Med. 28 2001 836-846
57. Wester H.J. Schottelius M. Scheidhauer K. et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labeled, carbohydrated analogue of octreotide Eur. J. Nucl. Med. Mol. Imaging 30 2003 117-122
58. Waldherr C. Pless M. Maecke H.R. et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC J. Nucl. Med. 43 2002 610-616
59. Reubi J.C. Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur. J. Nucl. Med. Mol. Imaging 30 2003 781-793
60. Scheidhauer K. Wolf I. Baumgartl H.J. et al. Biodistribution and kinetics of (131)I-labeled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma Eur. J. Nucl. Med. Mol. Imaging 29 2002 1276-1282
61. Forster G.J. Engelbach M.J. Brockmann J.J. et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPAoctreotide Eur. J. Nucl. Med. 28 2001 1743-1750
62. Brooks P.C. Stromblad S. Klemke R. et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin J. Clin. Invest. 96 1995 1815-1822
63. Haubner R. Wester H.J. Weber W.A. et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 61 2001 1781-1785
64. Janssen M.L. Oyen W.J. Dijkgraaf I. et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model Cancer Res. 62 2002 6146 6151
65. Dehdashti F. Grigsby P.W. Mintun M.A. et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report Int. J. Radiat. Oncol. Biol. Phys. 55 2003 1233-1238
66. Sorger D. Patt M. Kumar P. et al. [(18)F]Fluoroazomycinarabinofuranoside ((18)FAZA) and [(18)F]Fluoromisonidazole ((18)FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors Nucl. Med. Biol. 30 2003 317-326
67. Kubota K. Tada M. Yamada S. et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumor tissue Eur. J. Nucl. Med. 26 1999 750-757
68. Piert M. Machulla H.J. Reichel G. et al. Fluorine-18 labeled fluoroazomycin arabinoside (FAZA): imaging murine tumor hypoxia with improved biokinetics J. Nucl. Med. 43 2002 278P
69. Lehtio K. Oikonen V. Nyman S. et al. Quantifying tumor hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumor to plasma ratio Eur. J. Nucl. Med. Mol. Imaging 30 2003 101-108
70. Chao K.S. Bosch W.R. Mutic S. et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 49 2001 1171-1182
71. Peters K.B. Brown J.M. Tirapazamine: a hypoxia-activated topoisomerase II poison Cancer Res. 62 2002 5248-5253
72. Wainwright S. Axis and circumference: the cylindrical shape of plants and animals 1988 Harvard University Press Cambridge, MA